Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) dropped 3.3% on Monday . The stock traded as low as $3.70 and last traded at $3.87. Approximately 178,113 shares were traded during mid-day trading, a decline of 30% from the average daily volume of 254,496 shares. The stock had previously closed at $4.00.
Relmada Therapeutics Trading Down 1.3 %
The firm has a market cap of $116.46 million, a PE ratio of -1.18 and a beta of 0.19. The firm has a fifty day simple moving average of $5.17 and a two-hundred day simple moving average of $3.98.
Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) last announced its earnings results on Tuesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.04. Equities analysts expect that Relmada Therapeutics, Inc. will post -3.53 earnings per share for the current fiscal year.
Insider Activity at Relmada Therapeutics
Hedge Funds Weigh In On Relmada Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of RLMD. Stratos Wealth Partners LTD. purchased a new position in Relmada Therapeutics during the third quarter valued at $48,000. TD Asset Management Inc lifted its position in Relmada Therapeutics by 100.0% during the third quarter. TD Asset Management Inc now owns 25,000 shares of the company’s stock valued at $75,000 after purchasing an additional 12,500 shares in the last quarter. ADAR1 Capital Management LLC purchased a new position in Relmada Therapeutics during the fourth quarter valued at $243,000. Silverarc Capital Management LLC purchased a new position in Relmada Therapeutics during the third quarter valued at $300,000. Finally, Vestal Point Capital LP purchased a new position in Relmada Therapeutics during the fourth quarter valued at $476,000. 45.24% of the stock is currently owned by hedge funds and other institutional investors.
About Relmada Therapeutics
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
Featured Articles
- Five stocks we like better than Relmada Therapeutics
- How to Buy Cheap Stocks Step by Step
- High-Yield Texas Instruments Could Hit New Highs Soon
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Business Services Stocks Investing
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.